Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47,898,935
-
Number of holders
-
240
-
Total 13F shares, excl. options
-
50,084,803
-
Shares change
-
-1,034,054
-
Total reported value, excl. options
-
$2,655,680,021
-
Value change
-
-$87,203,336
-
Put/Call ratio
-
23.96%
-
Number of buys
-
125
-
Number of sells
-
-116
-
Price
-
$53.04
Significant Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q4 2021
299 filings reported holding HAE - HAEMONETICS CORP - Common Stock as of Q4 2021.
HAEMONETICS CORP - Common Stock (HAE) has 240 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 50,084,803 shares
.
Largest 10 shareholders include BlackRock Inc. (6,692,346 shares), WELLINGTON MANAGEMENT GROUP LLP (5,073,879 shares), VANGUARD GROUP INC (4,880,936 shares), Neuberger Berman Group LLC (3,876,521 shares), Capital Research Global Investors (2,049,133 shares), STATE STREET CORP (1,691,193 shares), FRANKLIN RESOURCES INC (1,467,570 shares), WESTFIELD CAPITAL MANAGEMENT CO LP (1,287,677 shares), LGT CAPITAL PARTNERS LTD. (1,216,059 shares), and Fisher Asset Management, LLC (1,194,645 shares).
This table shows the top 240 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.